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Abstract
Aims/hypothesis Insulin secretion in pancreatic islets is
dependent upon mitochondrial function and production of
ATP. The transcriptional coactivator peroxisome proliferator
activated receptor gamma coactivator-1 alpha (protein PGC-
1α;g e n ePPARGC1A) is a master regulator of mitochondrial
genes and its expression is decreased and related to impaired
oxidative phosphorylation in muscle from patients with
type 2 diabetes. Whether it plays a similar role in human
pancreatic islets is not known. We therefore investigated if
PPARGC1A expression is altered in islets from patients with
type 2 diabetes and whether this expression is influenced by
genetic (PPARGC1A Gly482Ser polymorphism) and epi-
genetic (DNA methylation) factors. We also tested if ex-
perimental downregulation of PPARGC1A expression in
human islets influenced insulin secretion.
Methods The PPARGC1A Gly482Ser polymorphism was
genotyped in human pancreatic islets from 48 non-diabetic
and 12 type 2 diabetic multi-organ donors and related to
PPARGC1A mRNA expression. DNA methylation of the
PPARGC1A promoter was analysed in pancreatic islets
from ten type 2 diabetic and nine control donors. Isolated
human islets were transfected with PPARGC1A silencing
RNA (siRNA).
Results PPARGC1A mRNA expression was reduced by
90% (p<0.005) and correlated with the reduction in insulin
secretion in islets from patients with type 2 diabetes. After
downregulation of PPARGC1A expression in human islets
by siRNA, insulin secretion was reduced by 41% (p≤0. 01).
We were able to ascribe reduced PPARGC1A expression in
islets to both genetic and epigenetic factors, i.e. a common
PPARGC1A Gly482Ser polymorphism was associated with
reduced PPARGC1A mRNA expression (p<0.00005) and
reduced insulin secretion (p<0.05). In support of an epi-
genetic influence, the PPARGC1A gene promoter showed a
twofold increase in DNA methylation in diabetic islets
compared with non-diabetic islets (p<0.04).
Conclusions/interpretation We have shown for the first time
that PPARGC1A might be important in human islet insulin
secretion and that expression of PPARGC1A in human islets
can be regulated by both genetic and epigenetic factors.
Keywords DNAmethylation.Epigenetic.
Geneexpression.Genetic.Human.Pancreaticislets.
PGC-1α.PPARGC1A.Type2diabetes
Abbreviations
HNF-1 hepatic nuclear factor 1
NA nicotinamide
PGC-1α peroxisome proliferator activated receptor
gamma coactivator-1 alpha
siRNA silencing RNA
STZ streptozotocin
Introduction
Type 2 diabetes is characterised by chronic hyperglycaemia
as a result of impaired pancreatic beta cell function and
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Pisa, Italyinsulin resistance in peripheral tissues, i.e. skeletal muscle,
adipose tissue and liver. Although each of these patho-
genic defects could be accounted for by specific mecha-
nisms, impaired ATP production as a consequence of
reduced oxidative phosphorylation might provide an in-
triguing common pathogenic pathway for all these defects.
The transcriptional coactivator peroxisome proliferator
activated receptor gamma coactivator-1 alpha (protein
PGC-1α; gene PPARGC1A) is an important factor regulat-
ing the expression of genes for oxidative phosphorylation
and ATP production in target tissues through coactivation
of nuclear receptors [1]. We have previously shown that the
expression of PPARGC1A and a set of genes involved in
oxidative phosphorylation is reduced in skeletal muscle
from patients with type 2 diabetes [2]. Furthermore, a
common polymorphism, Gly482Ser, in the PPARGC1A
gene has been associated with increased risk of type 2
diabetes and an age-related reduction in muscle PPARGC1A
expression [3–5]. In addition, genetic variation in the
PPARGC1A gene was associated with indices of beta cell
function [6]. Despite the central role of ATP for insulin
secretion, the function of PGC-1α in human pancreatic
islets and beta cells is less well established [7].
Obesity, reduced physical activity and ageing are well
known risk factors for type 2 diabetes. However, all
individuals exposed to an affluent environment do not
develop the disease. One likely reason is that genetic
variation modifies individual susceptibility to the environ-
ment. However, the environment could also modify genetic
risk factors by influencing expression of a gene by DNA
methylation or histone modifications. Cytosine residues oc-
curring in CG dinucleotides are targets for DNA methyl-
ation and gene expression is usually reduced when DNA
methylation takes place at a promoter. Whether DNA
methylation influences gene expression in target tissues
for type 2 diabetes and thereby the pathogenesis of the
disease remains to be demonstrated.
The present study investigated: (1) whether expression
of PPARGC1A is altered in human islets from patients with
type 2 diabetes; (2) if this expression is influenced by
genetic (the PPARGC1A Gly482Ser polymorphism) and
epigenetic (DNA methylation) factors; and (3) if expression
of PPARGC1A influences insulin secretion.
Methods
Multi-organ donors The characteristics of the 48 non-
diabetic and 12 type 2 diabetic multi-organ donors,
whose pancreases were processed for islet preparation,
are presented in Table 1. Pancreases were obtained and
processed with the approval of the regional Ethics
Committee.
Human pancreatic islets and experimental plan Isolated
pancreatic islets were prepared by collagenase digestion and
density gradient purification [8, 9]. After isolation, islets
were cultured free floating in M199 culture medium (Sigma-
Aldrich, St Louis, MO, USA) at 5.5 mmol/l glucose
concentration and studied within 3 days from isolation. Cell
viability, measured by Trypan Blue exclusion, was higher
than 90% in control and diabetic islets after 3 days in culture.
I n s u l i ns e c r e t i o ns t u d y Insulin secretion studies were
performed as previously described [8, 9]. Following a
45 min pre-incubation period at 3.3 mmol/l glucose, groups
of 30 islets of comparable size were kept at 37°C for 45 min
in KRB, 0.5% (wt/wt) albumin, pH 7.4, containing
3.3 mmol/l glucose. At the end of this period, the medium
was completely removed and replaced with KRB containing
either 3.3, 16.7 or 3.3 mmol/l glucose plus 20 mmol/l
arginine, or 3.3 mmol/l glucose plus 100 μmol/l glibencla-
mide. After an additional 45 min incubation period, the
medium was removed. Media (500 μl aliquots from the
10 ml incubation volume) were stored at −20°C until
insulin concentrations were measured by immunoradiomet-
ric assay (Pantec Forniture Biomediche, Turin, Italy).
Animals Streptozotocin (STZ)–nicotinamide (NA)-treated
male Wistar rats (2–3 months old) were administered
210 mg/kg NA i.p. (Sigma, St Louis, MO, USA)
dissolved in saline, 15 min before an i.v. injection of
60 mg/kg STZ (Sigma) that had been dissolved in citrate
buffer (pH 4.5) immediately before use. Control rats were
injected with vehicle alone. STZ–NA-treated animals had
stable hyperglycaemia (8.9–1 0 . 0m m o l / l )a n dt h e yw e r e
used for the experiments 5 weeks after diabetes was
induced. Pancreatic islets were isolated by the collage-
nase method using the procedure of pancreatic duct
cannulation and density gradient purification as described
elsewhere [10, 11].
Table 1 Clinical characteristics of type 2 diabetic and non-diabetic
donors
Non-diabetic
donors
Type 2 diabetic
donors
p value
n (male/female) 48 (30/18) 12 (6/6)
9 (7/2)
a 10 (5/5)
a
Age (years) 53.2±2.4 66.7±2.4 <0.05
54.2±3.5
a 65.1±2.6
a
BMI (kg/m
2) 24.8±0.6 27.1±1.0 <0.05
25.9±1.3
a 26.9±1.1
a
Gly/Gly (%)
b 53.3 27.3
Gly/Ser+Ser/Ser (%)
b 46.7 72.3
Data are expressed as mean±SEM
aDonors used for DNA methylation analysis
bPPARGC1A Gly482Ser polymorphism
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bred as described [12]. Inbred, normoglycaemic F344 rats
were purchased from Charles River Laboratories (Wilming-
ton, MA, USA) and maintained by sister–brother mating.
Transfer of GK alleles onto the genome of F344 rats by
repeated backcrossing (ten generations) established the
homozygous congenic strains F344.GK-Niddm1f (NIDD
M1F) and F344.GK-Niddm1i (NIDDM1I). NIDDM1F
carries 0.5% of the GK genotype (8 cM), based on genetic
distance, on a homozygous F344 genetic background.
NIDDM1F rats display hyperglycaemia accompanied by
fasting hyperinsulinaemia and increased epididymal fat,
implicating insulin resistance. NIDDM1I carries 0.8% of
the GK genotype (14 cM), and display hyperglycaemia and
insulin secretion defects [13–15]. Backcrossing was
designed to introduce mitochondrial DNA and chromo-
somes X plus Y from F344. The congenic strains were kept
constant by sister–brother mating for several generations. To
avoid effects of the oestrous cycle and other sex-specific
influences, only male rats were included in this study. Rats
were maintained at constant temperature and humidity in a
12 h light–dark cycle with free access to standard laboratory
chow pellets and water. All experiments were approved by
the local Ethics Committees. Isolated pancreatic islets were
prepared from rats at 8 weeks of age after a 6 h fast (08:00–
14:00 hours), by injection of a collagenase solution via the
bile–pancreatic duct [16].
Analysis of PPARGC1A mRNA expression in pancreatic
islets Total RNA was extracted from human islets, after
3 days in culture, using the RNeasy Protect Mini Kit
(Qiagen, Valencia, CA, USA). It was quantified by absorb-
ance at A260/A280 nm (ratio>1.65) in a Perkin-Elmer
spectrophotometer (Waltham, MA, USA) and its integrity
was assessed after electrophoresis in 1.0% (wt/wt) agarose
gels by ethidium bromide staining. Human and rat
PPARGC1A mRNA expression were quantified by RT-PCR
[8]. Gene-specific probes and primer pairs for PPARGC1A
(Assays-on-demands, human, Hs00173304_m1 and rat,
Rn00580241_A1; Applied Biosystems, Foster City, CA,
USA) were used. Each sample was run in duplicate and
the transcript quantity was normalised to the mRNA level
of cyclophilin A (human, 4326316E and rat Rn005747
62_A1; Applied Biosystems). For each probe/primer set, a
standard curve was generated, which was confirmed to
increase linearly with increasing amounts of cDNA.
Downregulation of PGC-1α in human islets using silencing
RNA (siRNA) In order to test whether inhibition of
PPARGC1A expression could directly modulate insulin
release, isolated human islets were transfected with
PPARGC1A siRNA by using Arrest-In Transfection (Open
Biosystem; Celbio, Pero, Italy). This is a polymeric
formulation developed and optimised for highly efficient
delivery of siRNA into the nucleus of suspension cells in
the presence of serum-containing medium. Pre-designed
Silencer siRNAs and Silencer non-targeting siRNAs (neg-
ative control) for PPARGC1A (Ambion, Austin, TX, USA)
were used. Transfection was performed according to the
manufacturer’s instructions. Briefly, islets obtained from
five pancreases were washed 12 times in KRB and exposed
for 10 min to free Ca
2+- and Mg
2+-KRB to allow cell
disaggregation. At the end of the incubation period, 400
islets per study point were re-suspended in 800 μl M199
medium (Sigma-Aldrich) added with adult bovine serum.
siRNA (80 nmol/l) was diluted in 100 μl M199, while
20 μg Arrest-In solution (Celbio) was dissolved in 100 μl
M199 and incubated for 10 min after rapid mixing to allow
formation of transfection complexes. Finally, 200 μl of this
solution were added into wells containing islets and
incubation was allowed for 48 h in a CO2 incubator at
37°C. At the end of the incubation period well volume was
doubled with M199 culture medium and samples were kept
in the incubator for another 48 h, when islets function,
viability, transfection efficiency (60% when measured by
Polyfectamine tied to a fluorescent probe) and gene
expression were evaluated.
Genotyping Genomic DNA was extracted from pancreatic
islets using a Wizard Genomic DNA Purification kit (Prom-
ega, Madison, WI, USA). The Gly482Ser (GGT→AGT)
polymorphism of PPARGC1A was genotyped using an allelic
discrimination assay performed with an ABI 7900 system
(Applied Biosystems), using PCR primers: 5′-CACTTCGG
TCATCCCAGTCAA-3′ (forward) and 5′-TTATCACTTT
CATCTTCGCTGTCATC-3′ (reverse), and TaqMan MGB
probes: Fam-5′-AGACAAGACCGGTGAA-3′ and Vic-5′-
CAGACAAGACCAGTGAA-3′ [5, 17].
DNA methylation A sequence starting 5,000 bp upstream
from the PPARGC1A translation start was used in Meth-
Primer (http://www.urogene.org/methprimer/index.html)t o
search for regions with CpG sites and PCR designs. A
PPARGC1A sequence 986–746 bases upstream from the
translationstartincludingfourpossibleDNA-methylation sites
and a putative hepatic nuclear factor 1 (HNF-1) binding
site, was selected and analysed for DNA methylation
(Fig. 1c). Genomic DNA, isolated from pancreatic islets of
nine non-diabetic and ten type 2 diabetic multi-organ donors,
was treated with bisulphite using the EZ DNA Methylation
Kit (Zymo Research, Orange, CA, USA). Bisulphite-modified
DNA was amplified by nested PCR with primers designed
using MethPrimer. Primer pair 1: 5′-TAGGGTATTAGGG
TTGGAATTTAATG-3′ (forward) and 5′-CCCATAACAA
TAAAAAATACCAACTC-3′ (reverse), and primer pair 2
(used for nested PCR): 5′-TATTTTAAGGTAGTTAGG
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TACCAACTCCC-3′ (reverse). The PCR products were then
cloned into a vector (TOPO TA Cloning Kit for Sequencing,
Invitrogen, Carlsbad, CA, USA) and ten colonies from each
donor were purified with a Miniprep kit (Qiagen). These
individual clones were sequenced using BigDye Terminator
v3.1 Cycle Sequencing Kit (Applied Biosystems). The
number of methylated sites was determined and divided by
the total number of methylation sites and then multiplied by
100 to show the percentage of methylation for each donor.
Statistical methods Differences in PPARGC1A mRNA ex-
pression, percentage of DNA methylation and insulin
secretion between the different groups studied were
analysed using Student’s t test or the non-parametric
Mann–Whitney test, where appropriate. Correlations were
calculated using Pearson correlation coefficients for nor-
mally distributed values and Spearman correlation coef-
ficients when normality was rejected. Log values were used
in the multivariate regression analysis. Differences in
expression between GK, F344, NIDDM1F and NIDDM1I
rats were analysed using one-way ANOVA, followed by a
Kruskal–Wallis Z test. All p values were two-tailed and p
values less than 0.05 were considered significant. Statistical
calculations were performed by NCSS software (NCSS
Statistical Software, Kaysville, UT, USA).
Results
The mRNA expression of PPARGC1A was markedly
reduced in pancreatic islets from type 2 diabetic compared
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Fig. 1 PPARGC1A mRNA ex-
pression in human pancreatic
islets is influenced by type 2
diabetes, a PPARGC1A
Gly482Ser polymorphism and
DNA methylation. The influ-
ence of a type 2 diabetes and
b the PPARGC1A Gly482Ser
polymorphism on PPARGC1A
mRNA expression in human
pancreatic islets. c The
PPARGC1A promoter sequence
investigated, showing the four
DNA methylation target sites;
−772, −903, −936 and −961 and
a putative binding-site for HNF-
1. d The influence of type 2
diabetes on DNA methylation of
the PPARGC1A promoter. The
influence of e type 2 diabetes
(T2D) and f the PPARGC1A
Gly482Ser polymorphism on
absolute insulin release (pmol
islet
−1 min
−1) in response to
16.7 mmol/l glucose. g Correla-
tions between PPARGC1A
mRNA expression and absolute
insulin release (pmol islet
−1
min
−1) in response to
16.7 mmol/l glucose in human
pancreatic islets (r=0.38,
p<0.05). Results are expressed
as mean±SEM. *p<0.05
618 Diabetologia (2008) 51:615–622with non-diabetic donors (1.06±0.63 vs 15.0±3.0; p<0.005;
Fig. 1a). Intriguingly, non-diabetic carriers of a PPARGC1A
482Ser allele, Gly/Ser or Ser/Ser genotype carriers had
markedly lower PPARGC1A mRNA expression compared
with carriers of the Gly/Gly genotype [Gly/Ser + Ser/Ser
3.43±0.94 (n=17) vs Gly/Gly 26.53±4.42 (n=17); p<
0.00005] (Fig. 1b). However, there was no difference in
PPARGC1A mRNA expression between non-diabetic carriers
of the Gly/Ser (3.9±4.0; n=11) or Ser/Ser (2.7±5.5; n=6)
genotypes. This demonstrates that the effect of the genotype
on gene expression is seen already in the pre-diabetic state.
The diabetic donors were significantly older and had higher
BMI than control donors (Table 1). We therefore tested
whether these factors might also relate to PPARGC1A expres-
sion in human islets using a multivariate regression analysis
including age, BMI and disease status as covariates. Only
disease status was significantly associated with PPARGC1A
expression in this analysis (r=1.04; p=0.0065).
We next evaluated whether epigenetic phenomena such
as DNA methylation would influence PPARGC1A expres-
sion in islets. Cytosine residues occurring in CG dinucleo-
tides are targets for DNA methylation, and gene expression
is usually reduced when DNA is methylated at the pro-
moter. We used bisulphite sequencing to assess DNA
methylation of four methylation target sites, −772, −903,
−936 and −961 in the PPARGC1A promoter in pancreatic
islets from the type 2 diabetic and non-diabetic human
multi-organ donors (Fig. 1c). Interestingly, there was an
approximately twofold increase in DNA methylation of the
PPARGC1A promoterofdiabeticcomparedwithnon-diabetic
human islets (10.5±2.7 vs 4.7±0.9%; p<0.04; Fig. 1d). Also
in this subset of donors, the PPARGC1A mRNA expression
was significantly reduced in diabetic compared with non-
diabetic islets (p=0.002). There was a trend towards an
inverse correlation between the level of DNA methylation
and PPARGC1A mRNA expression (r=−0.48; p=0.08, after
adjustment for disease status).
Insulin release (pmol islet
−1 min
−1) in response to
16.7 mmol/l glucose was reduced in type 2 diabetic com-
pared with non-diabetic islets (0.32±0.04 vs 0.55±0.05;
p<0.01) as well as in non-diabetic islets carrying the
PPARGC1A 482Ser allele (Gly/Ser+Ser/Ser) compared
with carriers of the Gly/Gly genotype (Gly/Ser+Ser/Ser
0.43±0.06 vs Gly/Gly 0.64±0.07; p<0.05; Fig. 1e–f). In
addition, the mRNA expression of PPARGC1A correlated
positively with glucose-mediated insulin release (r=0.38;
p<0.05; Fig. 1g). Moreover, the PPARGC1A Gly482Ser
polymorphism did not significantly affect basal insulin
secretion at 3.3 mmol/l glucose (Gly/Ser+Ser/Ser, 0.23±
0.01 vs Gly/Gly, 0.29±0.02; p=0.13), or insulin response
to arginine (Gly/Ser+Ser/Ser 0.48±0.05 vs Gly/Gly 0.53±
0.08; p=0.77) or glibenclamide (Gly/Ser+Ser/Ser 0.59±0.1
vs Gly/Gly 0.56±0.09; p=0.98).
Having seen the relationship between PPARGC1A ex-
pression and insulin secretion, we set out to determine
whether modulation of PPARGC1A expression would
influence insulin secretion. This was achieved by studying
insulin secretion after experimental downregulation of
PGC-1α in human islets transfected with PPARGC1A siRNA
(n=3–5 experiments). As shown in Fig. 2, transfection with
siRNA was associated with a 45% reduction in the mRNA
expression of PPARGC1A (p=0.01), 32% reduction in
insulin mRNA (p=0.05) and 41% reduction of the insulin
stimulation index (i.e. incremental folds above baseline
insulin release; p=0.01). Notably, no significant change
was seen in glucagon mRNA expression, suggesting that
the effect was primarily due to a downregulation of PGC-
1α in beta cells. As a negative control, transfection with
scrambled siRNA was not associated with any changes in
PPARGC1A (1.26±0.25), insulin (1.29±0.16) or glucagon
(0.99±0.15) mRNA expression (p>0.05).
The finding of reduced PPARGC1A expression in
human diabetic islets was somewhat surprising given an
earlier report of increased PGC-1α levels in islets from
diabetic mice (ob/ob) and rat (ZDF and pancreatectomised
rats) models [7]. To further explore species-specific differ-
ences we also measured PPARGC1A mRNA expression in
pancreatic islets from two diabetic rat models. PPARGC1A
expression was reduced in islets from STZ–NA diabetic
male Wistar rats compared with control animals (3.08±1.07
vs 10.26±1.12; p<0.009; Fig. 3a). Moreover, PPARGC1A
expression was reduced in islets from the congenic
NIDDM1I strain, which has insulin secretion defects,
compared with the insulin-resistant NIDDM1F strain (7.18±
1.79 vs 11.30±1.79; p<0.02) of the GK rat, an animal
model of polygenic type 2 diabetes (Fig. 3b ) .H o w e v e r ,n o
difference in PPARGC1A expression was found when
comparing islets from F344 or GK rat strains (Fig. 3b).
Discussion
The key results from the present study were that PPARGC1A
mRNA expression and insulin secretion were reduced in
pancreatic islets of patients with type 2 diabetes and in non-
diabetic carriers of a PPARGC1A 482Ser allele, a genotype
previously associated with the disease. Moreover, we
demonstrate that epigenetic mechanisms are likely to be
operative in the pathogenesis of type 2 diabetes since DNA
methylation of the PPARGC1A promoter was increased in
human diabetic islets. Experimental downregulation of
PPARGC1A expression in human islets by siRNA resulted
in decreased insulin secretion thereby demonstrating a
causal link between PGC-1α levels and insulin secretion.
Based on these observations we propose a model where
combinations of genetic and epigenetic factors can influ-
Diabetologia (2008) 51:615–622 619ence the level of PGC-1α in human islets and subsequently
glucose-stimulated insulin secretion.
The transcriptional coactivator PGC-1α is an important
factor regulating the expression of genes for oxidative
phosphorylation in a number of tissues including skeletal
muscle, liver and adipose tissue. We and others have
previously demonstrated reduced expression of PPARGC1A
and a set of genes involved in oxidative phosphorylation in
skeletal muscle from patients with type 2 diabetes [2, 18].
However, the level and role of PGC-1α in pancreatic islets
of patients with type 2 diabetes remained to be determined.
The present results indicate that the situation in human islets
mirrors the situation in skeletal muscle, since the expression
level of PPARGC1Awas reduced in human type 2 diabetic
islets, thus providing evidence for a common defect that may
simultaneously contribute to peripheral insulin resistance and
impairment of beta cell function.
In contrast to the present results in humans, elevated
PGC-1α levels have been reported in islets from diabetic
rodent models, ob/ob mice, ZDF rats and pancreatectom-
ised rats [7]. In these rodent models, the increase in PGC-
1α was associated with suppressed beta cell metabolism
and insulin release. This could reflect true species differ-
ences, but also differences in experimental conditions. To
address this issue, we determined: (1) the effect of inhib-
iting PGC-1α production by transfecting human pancreatic
islets with PPARGC1A siRNA; and (2) PPARGC1A ex-
pression in pancreatic islets of different rodent models with
experimental diabetes, i.e. STZ-diabetic Wistar rats and
congenic strains from the type 2 diabetes-like GK rat.
Silencing PGC-1α production was associated with con-
comitant reduction of insulin mRNA expression and insulin
release in response to glucose. This effect appears to be
highly specific for insulin regulation as it had no effect
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Fig. 3 PPARGC1A mRNA expression in rodent pancreatic islets.
a Male Wistar rats (2–3 months old) were treated with STZ–NA (n=5)
or vehicles (control; n=5) [10, 11] and PPARGC1A mRNA expression
together with the internal standard cyclophilin A was analysed in
pancreatic islets isolated from STZ–NA-treated animals showing
a stable hyperglycaemia (8.9–10.0 mmol glucose/l) and controls.
b PPARGC1A mRNA expression together with the internal standard
cyclophilin A was analysed in pancreatic islets prepared from rats at
8 weeks of age after a 6 h fast. GK rats (n=6) were obtained from the
Stockholm colony and bred as described [12]. Inbred, normoglycaemic
F344 (n=6) were purchased from Charles River Laboratories. Transfer
of GK alleles onto the genome of F344 rats by repeated backcrossing
(ten generations) established the homozygous congenic strains
NIDDM1F and NIDDM1I. NIDDM1F rats (n=6) carry 0.5% of the
GK genotype, based on genetic distance, on a homozygous F344
genetic background (8 cM) and display hyperglycaemia accompanied
by fasting hyperinsulinaemia, implicating insulin resistance. NIDDM1I
(n=6) carries 0.8% of the GK genotype (14 cM) and display insulin
secretion defects [13–15]. Results are expressed as mean±SEM.
*p<0.05
620 Diabetologia (2008) 51:615–622whatsoever on glucagon mRNA expression. The congenic
strains have been bred from the GK rat based upon low
insulin secretion or insulin resistance. In line with the
results observed in human islets, PPARGC1A expression
was reduced in islets from diabetic animals and in rat
strains with suppressed insulin secretion. Collectively, these
data support the notion that PPARGC1A expression is
reduced in animal models of diabetes and human diabetes,
and associated with impaired insulin secretion.
The risk of developing type 2 diabetes increases with
high-fat/high-energy diets, reduced physical activity and
age. However, not all individuals respond to the environ-
ment in the same way. This variation in response to envi-
ronmental factors has partially been ascribed to genetic
factors. The common Gly482Ser variant in the PPARGC1A
gene is a plausible candidate for such a genetic factor [3, 4].
We have previously shown that this polymorphism is
associated with an age-related decline in PPARGC1A gene
expression in human skeletal muscle [5]. The present study
shows that the same PPARGC1A risk allele, 482Ser, is
associated with reduced PPARGC1A expression and im-
paired insulin secretion in human islets. Thus, our results
provide the ground for a common genetic predisposition
towards type 2 diabetes contributing to both impaired
insulin action and secretion.
Reduced PPARGC1A expression may not simply reflect
an effect of the polymorphism per se but could also occur
through epigenetic phenomena such as increased DNA
methylation of the PPARGC1A promoter. Cytosine residues
occurring in CG dinucleotides are targets for DNA
methylation, and gene expression is usually reduced when
DNA methylation takes place at a promoter. Epigenetic
changes are well known to influence gene expression of
suppressor genes and oncogenes in cancer cells and
contribute to tumour growth [19]. Increased DNA methyl-
ation of the promoter of the PPARGC1A gene in type 2
diabetic human islets may contribute to beta cell dysfunc-
tion by similar mechanisms. To our knowledge, this is the
first study to demonstrate that DNA methylation may play a
role in regulating gene expression in human diabetic islets.
Our data suggest that PGC-1α can modulate glucose-
mediated insulin secretion in human islets, most likely via
an effect on ATP production as indicated by normal insulin
release in response to arginine and glibenclamide, which
stimulate insulin downstream of ATP. In support of such a
role, PPARGC1A mRNA expression correlated with glu-
cose-stimulated insulin release. Moreover, inhibition of
PPARGC1A expression by siRNA transfection in human
islets was associated with a decline in insulin mRNA and
insulin release. Similarly, in human type 2 diabetic islets,
reduced PPARGC1A mRNA levels were associated with
impaired glucose-mediated insulin secretion. The
PPARGC1A Gly482Ser polymorphism, which previously
has been associated with type 2 diabetes, was also
associated with reduced PPARGC1A expression and im-
paired insulin secretion in the human islets.
One caveat of this study could be that we did not
measure the protein level of PGC-1α in human islets.
However, we have previously demonstrated a significant
positive correlation between the PPARGC1A mRNA and
PGC-1α protein levels in human skeletal muscle [5] and we
therefore assume that this might also be the case in human
islets. The reduction in PPARGC1A expression in non-
diabetic carriers of a 482Ser allele was strong and factors
other than haploinsufficiency may therefore explain this
reduction. Moreover, whether the genotype influences
PPARGC1A expression in diabetic islets would be of
interest; however, the present study lacks statistical power
to perform this analysis. These relationships should be
addressed in future ad hoc studies.
In conclusion, we have shown that PPARGC1A mRNA
expression is reduced in islets from patients with type 2
diabetes and it is influenced by both genetic (Gly482Ser)
and epigenetic (DNA methylation) factors. This reduction
in PPARGC1A expression correlated with impaired glucose-
stimulated insulin secretion, which is known to require
ATP. Thereby, the present study provides two novel insights
into the molecular mechanisms of islet dysfunction in type
2 diabetes; first that a master transcription regulator of
oxidative phosphorylation, PGC-1α, may be involved and
second, that epigenetic factors like DNA methylation
should be considered when searching for the genetic causes
of type 2 diabetes.
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